Similar Articles
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Miraç Ayşen Ünsal
DOI: 10.4274/tnd.2019.00187
Prognostic-disability Biomarkers in Multiple Sclerosis: Review of the Literature from the Last Five Years
Nefati Kıylıoğlu
DOI: 10.4274/tnd.79836
Posterior Auricular Muscle Response: Observations in Brainstem Lesions
Yeşim Gülen Abanoz, Yasin Abanoz, Yasemin Akıncı, Ayşegül Gündüz, Eser Buluş, Melih Tütüncü, Sabahattin Saip, Meral Erdemir Kızıltan
DOI: 10.4274/tnd.57255
Evaluation of Seizure After Stroke in Stroke Unit
Yasemin Dinç, Gülnur Tekgöl Uzuner, Büşra Emir
DOI: 10.4274/tnd.78545
Peripheral Blood B Cell Distribution of Patients with Multiple Sclerosis
Joob Beuy, Viroj Wiwanitkit
DOI: 10.4274/tnd.86977
A Novel Technique Regarding the Pathophysiology of Normal Pressure Hydrocephalus: Glymphatic Magnetic Resonance Imaging?
Halil Önder
DOI: 10.4274/tnd.23911
A Rare Presentation of Spontaneous Intracranial Hypotension
Cihat Uzunköprü, Volkan Çakır, Şehnaz Arıcı, Yeşim Beckmann
DOI: 10.4274/tnd.98624
Mortality in Patients with Multiple Sclerosis
Sümeyra Şamlı, Murat Kürtüncü
DOI: 10.4274/tnd.15921
Fampridine Therapy in Multiple Sclerosis: We Should Think Twice!
Mohamed S A Mohamed
DOI: 10.4274/tnd.65882
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
Burcu Altunrende, Erkingül Birday, Mithat Kasap, Gülşen Akman Demir
DOI: 10.4274/tnd.62144
Quality of Life, Coping, and Social Support in Patients with Multiple Sclerosis: A Pilot Study
Oğuzhan Zengin, Ercüment Erbay, Buğra Yıldırım, Özgür Altındağ
DOI: 10.4274/tnd.37074
Flow Cytometry Analysis of Peripheral Blood B Cell Distribution of Patients with Multiple Sclerosis
Vuslat Yılmaz, Deniz Ak Tura, Canan Ulusoy, Duygu Özkan Yaşargün, Suzan Adın Çınar, Recai Türkoğlu
DOI: 10.4274/tnd.87523
Acute Spinal Pseudoathetosis
Mehmet Fevzi Öztekin, Dilara Mermi Dibek
DOI: 10.4274/tnd.27167
Weight Loss and Fingolimod
Nefati Kıylıoğlu
DOI: 10.4274/tnd.87528
Atrial Myxoma and Hypersomnia
Ahmet Özşimşek
DOI: 10.4274/tnd.37084
The Effect of Ocrelizumab in the Treatment of Multipl Sclerosis
Şenay Yıldız Çelik
DOI: 10.4274/tnd.71354
Amiselimod: A New Oral Agent in the Treatment of Multiple Sclerosis
Ahmed Serkan Emekli
DOI: 10.4274/tnd.90018
The Predictive Role of NEDA in the Long-Term Course of Multiple Sclerosis
Özgü Kizek
DOI: 10.4274/tnd.65391
The Neurophysiologic Frequency of Hereditary Neuropathy with Liability to Pressure Palsy in Entrapment Neuropathies
F Gökçem Yıldız, Gülay Nurlu, Sevim Erdem Özdamar, Çağrı Mesut Temuçin
DOI: 10.4274/tnd.70446
Does Serum Vitamin D Level During Pregnancy Influence the Risk of Multiple Sclerosis?
Tuncay Gündüz
DOI: 10.4274/tnd.28566